Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo
Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on preliminary encouraging safety and effectiveness data. “We continue to see encouraging efficacy and safety data from the prostate cancer cohort in COSMIC-021,” Gisela Schwab, MD, Exelixis’ president of product development and medical affairs, and chief medical officer, said in a press release. “Expanding this cohort by an additional 50 patients will allow us to further document how the combination of cabozantinib and atezolizumab may benefit this patient population as we assess our potential regulatory plans for the combination and prepare to initiate a Phase 3 pivotal trial,” Schwab added. With this decision, the group will now include up to 130 mCRPC patients in a trial that had already expanded from 30 to 80 patients in July 2019. More information on contacts and recruitment locations can be found here. Initial data from this group of mCRPC patients will be presented on Feb. 13 at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium, which will take place in San Francisco, California. Exelixis’ Cabometyx works by suppressing the activity of specific enzymes called tyrosine kinases — which are abnormally activated or found in higher-than-normal levels in some types of cancers — and by promoting anti-tumor immune responses. It is approved for the treatment of certain types of kidney cancer, and liver cancer. Tecentriq, developed by Genentech — a member of the Roche Group — is an immune checkpoint inhibitor designed to block PD-L1, a protein found in high levels on the surface
Subscribe or to access all post and page content.